Cargando…

NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities

Nicotinamide adenine dinucleotide (NAD(+)) is an essential and pleiotropic coenzyme involved not only in cellular energy metabolism, but also in cell signaling, epigenetic regulation, and post-translational protein modifications. Vascular disease risk factors are associated with aberrant NAD(+) meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdellatif, Mahmoud, Bugger, Heiko, Kroemer, Guido, Sedej, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Lipidology and Atherosclerosis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133775/
https://www.ncbi.nlm.nih.gov/pubmed/35656147
http://dx.doi.org/10.12997/jla.2022.11.2.111
_version_ 1784713645063667712
author Abdellatif, Mahmoud
Bugger, Heiko
Kroemer, Guido
Sedej, Simon
author_facet Abdellatif, Mahmoud
Bugger, Heiko
Kroemer, Guido
Sedej, Simon
author_sort Abdellatif, Mahmoud
collection PubMed
description Nicotinamide adenine dinucleotide (NAD(+)) is an essential and pleiotropic coenzyme involved not only in cellular energy metabolism, but also in cell signaling, epigenetic regulation, and post-translational protein modifications. Vascular disease risk factors are associated with aberrant NAD(+) metabolism. Conversely, the therapeutic increase of NAD(+) levels through the administration of NAD(+) precursors or inhibitors of NAD(+)-consuming enzymes reduces chronic low-grade inflammation, reactivates autophagy and mitochondrial biogenesis, and enhances oxidative metabolism in vascular cells of humans and rodents with vascular pathologies. As such, NAD(+) has emerged as a potential target for combatting age-related cardiovascular and cerebrovascular disorders. This review discusses NAD(+)-regulated mechanisms critical for vascular health and summarizes new advances in NAD(+) research directly related to vascular aging and disease, including hypertension, atherosclerosis, coronary artery disease, and aortic aneurysms. Finally, we enumerate challenges and opportunities for NAD(+) repletion therapy while anticipating the future of this exciting research field, which will have a major impact on vascular medicine.
format Online
Article
Text
id pubmed-9133775
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Korean Society of Lipidology and Atherosclerosis
record_format MEDLINE/PubMed
spelling pubmed-91337752022-06-01 NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities Abdellatif, Mahmoud Bugger, Heiko Kroemer, Guido Sedej, Simon J Lipid Atheroscler Review Nicotinamide adenine dinucleotide (NAD(+)) is an essential and pleiotropic coenzyme involved not only in cellular energy metabolism, but also in cell signaling, epigenetic regulation, and post-translational protein modifications. Vascular disease risk factors are associated with aberrant NAD(+) metabolism. Conversely, the therapeutic increase of NAD(+) levels through the administration of NAD(+) precursors or inhibitors of NAD(+)-consuming enzymes reduces chronic low-grade inflammation, reactivates autophagy and mitochondrial biogenesis, and enhances oxidative metabolism in vascular cells of humans and rodents with vascular pathologies. As such, NAD(+) has emerged as a potential target for combatting age-related cardiovascular and cerebrovascular disorders. This review discusses NAD(+)-regulated mechanisms critical for vascular health and summarizes new advances in NAD(+) research directly related to vascular aging and disease, including hypertension, atherosclerosis, coronary artery disease, and aortic aneurysms. Finally, we enumerate challenges and opportunities for NAD(+) repletion therapy while anticipating the future of this exciting research field, which will have a major impact on vascular medicine. Korean Society of Lipidology and Atherosclerosis 2022-05 2022-04-06 /pmc/articles/PMC9133775/ /pubmed/35656147 http://dx.doi.org/10.12997/jla.2022.11.2.111 Text en Copyright © 2022 The Korean Society of Lipid and Atherosclerosis. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Abdellatif, Mahmoud
Bugger, Heiko
Kroemer, Guido
Sedej, Simon
NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities
title NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities
title_full NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities
title_fullStr NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities
title_full_unstemmed NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities
title_short NAD(+) and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities
title_sort nad(+) and vascular dysfunction: from mechanisms to therapeutic opportunities
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133775/
https://www.ncbi.nlm.nih.gov/pubmed/35656147
http://dx.doi.org/10.12997/jla.2022.11.2.111
work_keys_str_mv AT abdellatifmahmoud nadandvasculardysfunctionfrommechanismstotherapeuticopportunities
AT buggerheiko nadandvasculardysfunctionfrommechanismstotherapeuticopportunities
AT kroemerguido nadandvasculardysfunctionfrommechanismstotherapeuticopportunities
AT sedejsimon nadandvasculardysfunctionfrommechanismstotherapeuticopportunities